First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC) Meeting Abstract

  

Authors:	Bianchini, D.; Omlin, A. G.; Pezaro, C. J.; Mukherji, D.; Estelles, D. L.; Zivi, A.; Ferraldeschi, R.; Crespo, M.; Buchbinder, A.; Attard, G.; Scher, H. I.; De Bono, J. S.; Danila, D. C.
Abstract Title:	First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC)
Meeting Title:	49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	31
Issue:	15 Suppl.
Meeting Dates:	2013 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2013-05-20
Language:	English
ACCESSION:	WOS:000335419601650
PROVIDER:	wos
DOI:	10.1200/jco.2013.31.15_suppl.5052
Notes:	Meeting Abstract: 5052 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/128628